Bavarian Nordic A/S (BVNRY)
| Market Cap | 1.67B |
| Revenue (ttm) | 1.01B |
| Net Income (ttm) | 211.42M |
| Shares Out | 233.75M |
| EPS (ttm) | 2.74 |
| PE Ratio | 2.61 |
| Forward PE | 0.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,138 |
| Open | 7.15 |
| Previous Close | 7.11 |
| Day's Range | 7.15 - 7.15 |
| 52-Week Range | 5.95 - 10.65 |
| Beta | 1.33 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About BVNRY
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phas... [Read more]
News
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, April 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding mana...
Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S
COPENHAGEN, Denmark, April 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results:
Morris & Dickson is the First U.S. Distributor for Bavarian Nordic's JYNNEOS®, the Only FDA-approved Mpox Vaccine
SHREVEPORT, La.--(BUSINESS WIRE)--Morris & Dickson is proud to announce it is the first U.S. distributor of Bavarian Nordic's newly launched mpox vaccine, JYNNEOS®. As the only FDA-approved mpox vacci...
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant...
Bavarian Nordic A/S – Notice Convening Annual General Meeting
COPENHAGEN, Denmark, March 21, 2024 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland
COPENHAGEN, Denmark, March 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved JYNNEOS® (MVA-BN) for active immunization...
Bavarian Nordic Publishes Annual Report 2023
COPENHAGEN, Denmark, March 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2023. The consolidated, audited results were in line with the preliminary results, announced ...
Bavarian Nordic's Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency
COPENHAGEN, Denmark, February 23, 2024 – Bavarian Nordic A/S (OMX: BAVA) (“the Company”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Bavarian Nordic delivered record financial results in 2023
COPENHAGEN, Denmark, February 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today reports preliminary, unaudited financial results for 2023 and financial guidance for 2024. Furthermore, the Company provi...
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic
COPENHAGEN, Denmark, December 13, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a new long-term incentive program for Executive Management...
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
COPENHAGEN, Denmark, November 30, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 1,692,300 as a consequence of employees' e...
Bavarian Nordic to hold Capital Markets Days in February 2024
COPENHAGEN, Denmark, November 22, 2023 – Bavarian Nordic A/S (OMX: BAVA) will hold a series of capital markets days in February 2024 for investors and analysts across Europe and the U.S.
Bavarian Nordic Announces Interim Results for the First Nine Months of 2023
COPENHAGEN, Denmark, November 16, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2023 and business progress for the third quarter of ...
US CDC panel recommends Bavarian Nordic's vaccine for adults at risk of mpox
Bavarian Nordic said on Wednesday the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has voted in favor of recommending the routine use of ...
Bavarian Nordic's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk
COPENHAGEN, Denmark, October 25, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (A...
Bavarian Nordic Awarded Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve
COPENHAGEN, Denmark, September 13, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded another contract valued at more than EUR 11 million to supply its MVA-BN® smallpox v...
Bavarian Nordic Provides Update on COVID-19 Booster Vaccine Program
COPENHAGEN, Denmark, August 31, 2023 – Bavarian Nordic A/S (OMX: BAVA) today reported additional Phase 3 results and provided an update on the development program for its cVLP-based COVID-19 booster v...
Bavarian Nordic Announces First Half 2023 Results
COPENHAGEN, Denmark, August 23, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first half of 2023 and released its financial calenda...
Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents
COPENHAGEN, Denmark, August 6, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today positive topline results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial ( NCT05072080 ...
Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. Government
COPENHAGEN, Denmark, August 3, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strat...
Bavarian Nordic to discontinue RSV vaccine programme
Denmark-based Bavarian Nordic said on Saturday it was discontinuing its respiratory syncytial virus (RSV) vaccine programme as its Phase 3 clinical trial did not meet all the primary goals of preventi...
Bavarian Nordic Provides Update on RSV Vaccine Program
COPENHAGEN, Denmark, July 22, 2023 – Bavarian Nordic A/S (OMX: BAVA) today announced that its Phase 3 clinical trial of MVA-BN® RSV, a respiratory syncytial virus (RSV) vaccine candidate for adults ≥6...
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
COPENHAGEN, Denmark, June 27, 2023 – Bavarian Nordic A/S (OMX: BAVA) today reported topline results from a Phase 3 non-inferiority clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 boost...
Bavarian Nordic to Supply Smallpox Vaccines for EU Strategic Reserve
COPENHAGEN, Denmark, June 23, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded a contract valued at EUR 10 million to supply its smallpox vaccine to rescEU, a strategic...
Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age
COPENHAGEN, Denmark, June 20, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today the initial safety and immunogenicity results from a randomized, double-blind, placebo-controlled Phase 3 clinical ...